Last updated: August 1, 2026
Actavis Elizabeth LLC is a U.S. generic-drug operating company associated with the Actavis, Allergan and Teva corporate lineage. Its market position rests on abbreviated new drug application (ANDA) approvals, high-volume solid oral products, controlled-substance capabilities, manufacturing scale and access to Teva’s global generic portfolio. The company does not operate as an independent publicly reporting pharmaceutical group, so product-level revenue, patent ownership and pipeline data must be assessed through Teva filings, FDA records, Orange Book listings and litigation databases.
Actavis Elizabeth’s strongest competitive advantages are regulatory infrastructure, manufacturing capacity and portfolio breadth. Its principal weaknesses are generic price erosion, customer concentration, product commoditization, regulatory exposure and competition from India-based and U.S.-based manufacturers.
What is Actavis Elizabeth and who owns the company?
Actavis Elizabeth LLC is a U.S. legal entity used in the commercialization and manufacturing structure of Actavis-branded generic medicines. The Actavis generic business became part of Allergan after Actavis acquired Forest Laboratories in 2014 and changed its corporate name to Actavis plc. Teva Pharmaceutical Industries Ltd. acquired Allergan’s global generic business in 2016 for approximately $40.5 billion, creating the current corporate connection between Actavis Elizabeth and Teva’s generic operations (Teva Pharmaceutical Industries Ltd., 2016).
| Item |
Position |
| Legal entity |
Actavis Elizabeth LLC |
| Historical parent |
Actavis plc, later Allergan |
| Current corporate affiliation |
Teva Pharmaceutical Industries Ltd. |
| Primary business |
Generic pharmaceuticals and related commercial operations |
| Core market |
United States and international generic markets |
| Public-company reporting |
Consolidated within Teva; no standalone Actavis Elizabeth revenue disclosure |
| Principal regulatory pathway |
FDA ANDA approvals |
| Key legal relevance |
ANDA applicant, manufacturer, distributor or litigation party depending on product |
The corporate structure matters because Actavis Elizabeth’s commercial strength cannot be measured through a standalone public income statement. Teva reports North America and global generic performance at segment level rather than assigning sales, margin or research spending to each Actavis legal entity.
How strong is Actavis Elizabeth’s market position in generic pharmaceuticals?
Actavis Elizabeth has a strong institutional position but is not generally the primary commercial brand visible to patients or pharmacies. Its products compete through FDA approval status, supply reliability, price, formulary access, wholesaler relationships and launch timing after reference-drug patent or regulatory exclusivity expiry.
The company benefits from Teva’s position as one of the world’s largest generic-drug companies. Teva reported hundreds of generic medicines across multiple dosage forms and markets, with a U.S. portfolio covering oral solid products, injectables, respiratory products, complex generics and specialty medicines (Teva Pharmaceutical Industries Ltd., 2024).
Competitive positioning by capability
| Capability |
Actavis Elizabeth position |
Competitive implication |
| Portfolio breadth |
High through Teva’s consolidated generic portfolio |
Supports bundled contracting with wholesalers and payers |
| U.S. regulatory capability |
Strong |
Enables repeated ANDA filings and Paragraph IV strategies |
| Manufacturing scale |
Strong, subject to site-specific capacity |
Supports large-volume launches and supply continuity |
| Brand recognition |
Moderate to low at patient level |
Generic purchasing decisions rely on channel relationships |
| Complex generics |
Stronger than smaller regional manufacturers through Teva |
Creates higher barriers than conventional tablets |
| Pricing power |
Limited in commodity products |
Multiple ANDA filers rapidly compress prices |
| Litigation resources |
High relative to small generic companies |
Supports patent challenges and settlement negotiations |
| Exposure to enforcement |
Material |
Large-scale generic operations attract FDA, DOJ and private litigation scrutiny |
Actavis Elizabeth’s market position is strongest where scale, regulatory complexity or manufacturing requirements limit the number of viable suppliers. Its position is weaker in simple immediate-release tablets and capsules, where several approved ANDA holders can enter quickly and drive prices downward.
What products and dosage forms are associated with Actavis Elizabeth?
Actavis Elizabeth has been associated with a broad range of generic dosage forms, including:
- Immediate-release tablets and capsules
- Extended-release and delayed-release products
- Oral solutions and suspensions
- Topical products
- Injectable medicines
- Controlled substances
- Complex formulations and drug-device combinations through Teva’s broader portfolio
The precise product set changes as ANDAs transfer, approvals expire, products are discontinued or manufacturing responsibilities move among Teva affiliates. FDA’s Drugs@FDA and Orange Book databases provide the most reliable product-level record for approved applications, applicants and listed patents (U.S. Food and Drug Administration, 2024a, 2024b).
What formulations are protected or commercially differentiated?
Actavis Elizabeth competes in several formulation categories where technical development can delay substitution or reduce the number of competing suppliers:
| Formulation category |
Competitive barrier |
| Extended-release tablets |
Release-control technology, dissolution testing and bioequivalence |
| Delayed-release products |
Enteric coating and stability requirements |
| Complex injectables |
Sterility, container closure and manufacturing validation |
| Inhalation products |
Device performance, formulation equivalence and drug delivery |
| Transdermal systems |
Adhesion, delivery rate and in vitro or clinical equivalence |
| Controlled substances |
Manufacturing controls, quotas, diversion monitoring and DEA compliance |
Formulation patents generally belong to the brand sponsor or a product-specific patent owner, not automatically to Actavis Elizabeth. Actavis may challenge those patents through a Paragraph IV certification or enter under a settlement agreement. The company’s own intellectual property typically concerns formulation processes, manufacturing methods, analytical methods or delivery technologies.
What is the Orange Book status of Actavis Elizabeth products?
Actavis Elizabeth generally appears in FDA records as an ANDA applicant or as a legal entity associated with an approved generic application. The Orange Book primarily lists approved reference drugs and patents submitted by NDA holders. It does not function as a complete registry of every patent or commercial right affecting a generic manufacturer.
For each product, the relevant record should be separated into four categories:
- The reference listed drug and NDA holder.
- The ANDA applicant and approval date.
- Listed patents and exclusivity attached to the reference product.
- Litigation, settlement or regulatory restrictions affecting the generic launch.
An ANDA approval does not establish immediate market entry. Launch timing can remain restricted by:
- Unexpired Orange Book patents
- 180-day generic exclusivity held by a first Paragraph IV filer
- Pediatric exclusivity
- Three-year clinical-investigation exclusivity
- New chemical entity exclusivity
- Court injunctions
- Settlement terms
- Manufacturing or inspection deficiencies
The Orange Book must therefore be reviewed product by product. Actavis Elizabeth has no single company-wide Orange Book expiration date.
When does Actavis Elizabeth lose exclusivity?
Actavis Elizabeth is a generic manufacturer and usually does not hold the reference-drug exclusivity that controls initial market entry. Its commercial rights depend on the approval and launch status of specific ANDAs.
Generic-entry timeline
| Event |
Commercial effect |
| ANDA filing with Paragraph IV certification |
Creates potential patent litigation |
| Brand-company lawsuit within 45 days |
Can trigger a 30-month stay of FDA approval |
| First ANDA approval |
May establish 180-day generic exclusivity |
| Patent expiration |
Removes the relevant patent barrier |
| Regulatory exclusivity expiration |
May permit additional ANDA approvals |
| Commercial launch |
Begins price competition and volume capture |
| Additional entrants |
Usually accelerate price erosion |
For a product where Actavis Elizabeth is a first Paragraph IV filer, its commercial advantage may depend on the scope and enforceability of the challenged patents, the outcome of litigation, and whether another applicant also qualifies for first-filer status. If it is a later filer, the company may face delayed approval or entry after the first filer’s exclusivity period.
Which companies compete with Actavis Elizabeth?
Actavis Elizabeth competes with large integrated generic manufacturers, specialty generic companies and lower-cost contract or offshore suppliers.
Principal competitor groups
| Competitor |
Competitive strength |
| Sandoz |
Broad global generic and biosimilar portfolio |
| Viatris |
Large U.S. portfolio and established commercial infrastructure |
| Lupin |
Strong U.S. ANDA pipeline and complex generics |
| Sun Pharma |
Specialty, complex generic and branded-generic capabilities |
| Dr. Reddy’s Laboratories |
Cost-efficient global generic development |
| Cipla |
Respiratory and complex product capabilities |
| Aurobindo Pharma |
High-volume U.S. ANDA portfolio and manufacturing scale |
| Amneal Pharmaceuticals |
U.S. commercial focus and complex generics |
| Endo and Par Pharmaceutical assets |
Established U.S. generic presence, subject to portfolio changes |
| Hikma Pharmaceuticals |
Injectable and hospital products |
Competition varies by molecule. A simple tablet can have numerous approved suppliers, while an injectable, inhaled product or complex modified-release dosage form may have only a small number of meaningful competitors.
How does Actavis Elizabeth compare with Teva, Viatris and Sandoz?
Actavis Elizabeth has an advantage through Teva’s scale but lacks the standalone transparency of publicly reported competitors.
| Factor |
Actavis Elizabeth through Teva |
Viatris |
Sandoz |
| Corporate scale |
Very high |
Very high |
Very high |
| U.S. generic reach |
Strong |
Strong |
Strong |
| Complex generics |
Strong |
Strong |
Strong |
| Biosimilars |
Access through Teva portfolio |
Significant portfolio |
Major strategic focus |
| Standalone financial disclosure |
No |
Yes, at company level |
Yes, at company level after Novartis separation |
| Commercial model |
Teva-integrated |
Integrated global platform |
Generic and biosimilar specialist |
| Key risk |
Portfolio rationalization and price erosion |
Debt, pricing and portfolio execution |
Manufacturing, pricing and launch execution |
Actavis Elizabeth’s practical advantage is access to Teva’s regulatory, legal and supply-chain infrastructure. Its disadvantage is that strategic decisions may prioritize Teva-wide portfolio economics rather than the growth of the Actavis Elizabeth entity itself.
What patent litigation affects Actavis Elizabeth?
Actavis Elizabeth may participate in patent litigation involving ANDA filings, particularly where it seeks early entry into markets protected by formulation, method-of-use or compound patents. Typical litigation issues include:
- Validity of the asserted patent
- Infringement under the ANDA filing
- Written description and enablement
- Obviousness
- Claim construction
- Patent-term adjustment
- Skinny-label or section viii carve-outs
- Induced infringement based on labeling
- Regulatory exclusivity and 30-month stays
The litigation record must be tied to a specific drug and docket. Company-wide conclusions are unreliable because an adverse judgment for one product does not necessarily affect other Actavis Elizabeth products.
How do settlement agreements affect generic launch?
Generic settlements can establish a negotiated entry date before patent expiration. Terms may include:
- An agreed launch date
- A license to sell before patent expiration
- No-admission clauses
- Supply or distribution arrangements
- Restrictions on authorized generic competition
- Patent litigation dismissal
- Contingent entry based on another challenger’s outcome
Settlements involving Actavis-related entities have historically required scrutiny under the Federal Trade Commission’s reverse-payment framework. The commercial value depends on the agreed entry date, expected number of competitors, market size and whether the brand sponsor launches an authorized generic.
What Paragraph IV challenge risks exist?
Paragraph IV litigation creates both upside and downside for Actavis Elizabeth.
Potential benefits
- Early launch before patent expiry
- First-filer exclusivity
- Higher gross margins during limited competition
- Strategic leverage in settlement negotiations
- Faster access to large branded markets
Principal risks
- Litigation costs
- 30-month approval stay
- Injunction or adverse validity ruling
- Loss of first-filer status
- Damages exposure in exceptional cases
- Launch-at-risk liability
- Rapid price erosion after multiple approvals
The highest-value opportunities usually involve products with large annual sales, weak patent positions and limited initial competition. The risk-adjusted value falls when the reference product has multiple overlapping patents, strong formulation claims or a credible pediatric or regulatory exclusivity position.
Does Actavis Elizabeth face biosimilar risk?
Actavis Elizabeth faces biosimilar competition risk indirectly through Teva’s broader portfolio and directly where its commercial operations participate in biologic or complex-product markets. Biosimilars require different development, manufacturing and regulatory capabilities from conventional ANDAs.
The U.S. biosimilar pathway is governed by the Biologics Price Competition and Innovation Act and FDA’s 351(k) framework. Relevant barriers include:
- Reference-product exclusivity
- Interchangeability requirements
- Manufacturing comparability
- Immunogenicity assessment
- Patent dance or patent litigation
- Limited payer coverage
- Hospital contracting
- Cold-chain and supply requirements
Teva has partnered with or commercialized biosimilar products, including through collaborations with major biotechnology companies. Biosimilar competition can reduce prices, but entry is slower and more capital-intensive than conventional generic competition (U.S. Food and Drug Administration, 2024c).
What manufacturing and intellectual-property barriers affect Actavis Elizabeth?
Manufacturing is a competitive asset only when it delivers consistent quality, sufficient capacity and reliable regulatory compliance. Actavis Elizabeth and Teva face the same industry-wide risks as other large generic manufacturers:
- FDA warning letters and Form 483 observations
- Product recalls
- Data-integrity findings
- Supply interruptions
- API shortages
- Site-transfer delays
- Serialization and traceability requirements
- Controlled-substance compliance
- Environmental and occupational controls
Intellectual-property barriers are product-specific. They include compound patents, polymorph patents, salt or crystal-form patents, formulation patents, process patents, device patents and method-of-use claims. A generic manufacturer’s ability to design around those rights can determine whether an ANDA reaches approval and whether launch occurs before patent expiry.
What revenue exposure does Actavis Elizabeth represent?
Actavis Elizabeth does not publish standalone revenue. Teva reports generic performance by geographic and business segment, meaning external investors cannot directly isolate:
- Actavis Elizabeth net sales
- Product-level gross margin
- Litigation-related revenue
- Market share by dosage form
- R&D spending attributable to the entity
- Manufacturing contribution by site
Revenue exposure should therefore be modeled at the molecule, product-family and Teva segment levels. Key variables include annual branded sales before generic entry, expected number of approved competitors, launch timing, dosage-form complexity, payer concentration and the probability of authorized-generic competition.
Generic launch scenarios
| Scenario |
Expected commercial outcome |
| Sole or first entrant |
High initial share and stronger margins |
| Two to three entrants |
Meaningful volume with rapid price decline |
| Five or more entrants |
Commodity economics and limited margin |
| Launch after patent expiry |
Lower legal risk but reduced early-entry value |
| Launch at risk |
Potentially high return with substantial liability |
| Complex generic launch |
Slower adoption but less immediate competition |
How strong is the Actavis Elizabeth patent estate?
Actavis Elizabeth’s company-level patent estate is less important than its product-specific regulatory and technical portfolio. Teva’s broader IP assets may include:
- Formulation patents
- Manufacturing-process patents
- Analytical methods
- Drug-delivery systems
- Device-related patents
- Biosimilar development know-how
- Trade secrets and process controls
The strongest protection usually comes from rights that are difficult to design around and supported by a defensible manufacturing process. Conventional composition-of-matter patents generally belong to the innovator. Actavis Elizabeth’s strategic value often comes from challenging, avoiding or licensing those rights rather than owning them.
What is the FDA regulatory status of Actavis Elizabeth?
Actavis Elizabeth products are regulated through FDA approval, manufacturing oversight, post-market surveillance and controlled-substance requirements where applicable. Relevant FDA data sources include:
- Drugs@FDA for approved applications
- Orange Book for reference drugs and listed patents
- FDA Drug Shortages database
- FDA enforcement and recall notices
- FDA inspection and compliance records
- Purple Book for licensed biologics and biosimilars
FDA status can change through approval, tentative approval, manufacturing-site transfer, labeling revision, product discontinuation, recall or withdrawal. A product listed as approved is not necessarily commercially available at full scale.
What licensing deals affect Actavis Elizabeth’s strategy?
Licensing and collaboration agreements are generally negotiated at the Teva or affiliate level rather than disclosed as Actavis Elizabeth transactions. Strategic arrangements can cover:
- Biosimilar development
- Complex generic technologies
- Inhalation devices
- Injectable products
- Regional commercialization
- API supply
- Authorized generic distribution
- Manufacturing rights
The commercial effect depends on territory, exclusivity, milestone obligations, profit sharing, supply commitments and termination rights. Teva’s global platform allows it to combine internal development with external licensing, reducing dependence on a single manufacturing or R&D site.
Geographic coverage and expansion prospects
Actavis Elizabeth is principally relevant to the U.S. market, while Teva provides international coverage across North America, Europe, emerging markets and selected specialty markets. Geographic expansion is constrained by:
- Country-specific registrations
- Local patent rights
- Pricing controls
- Tender systems
- Reference-pricing rules
- Local manufacturing requirements
- Import restrictions
- Pharmacovigilance obligations
A product that is commercially attractive in the United States may produce limited returns in Europe or emerging markets because of lower reimbursement, government tenders and earlier price compression.
Key Takeaways
- Actavis Elizabeth is a Teva-affiliated U.S. generic-drug entity, not a standalone publicly reporting company.
- Its competitive strengths are regulatory scale, manufacturing infrastructure, broad product access and litigation resources.
- Its primary weaknesses are generic price erosion, regulatory exposure and limited product-level financial transparency.
- Orange Book and patent analysis must be performed by molecule, dosage form and ANDA, not at the company level.
- Paragraph IV filings can create high-value early-entry opportunities but expose the company to litigation, approval delays and launch-at-risk liability.
- Complex generics, injectables, inhaled products and controlled substances offer stronger barriers than conventional tablets.
- Biosimilars create both a growth opportunity and a higher technical, legal and capital burden.
- Revenue exposure should be estimated through Teva segment disclosures and product-level market data because Actavis Elizabeth does not disclose standalone sales.
- Competitive pressure comes from Viatris, Sandoz, Lupin, Sun Pharma, Dr. Reddy’s, Aurobindo, Amneal, Cipla and Hikma, with intensity varying by product.
- Manufacturing compliance and reliable supply are as important to market position as patent strategy.
FAQs
Is Actavis Elizabeth the same company as Teva?
No. Actavis Elizabeth LLC is a legal entity associated with Teva’s generic operations. Teva is the public parent and reports consolidated financial results.
Does Actavis Elizabeth own the patents for the drugs it sells?
Usually not. Many patents covering generic products belong to the branded reference-drug sponsor. Actavis Elizabeth may own process or formulation rights or challenge the brand patents through an ANDA filing.
Can Actavis Elizabeth launch a generic before patent expiration?
Yes, if it obtains a license, wins or settles patent litigation, relies on a valid Paragraph IV strategy, or uses a permitted section viii labeling carve-out. Launch timing depends on the specific product.
Where can investors verify Actavis Elizabeth product approvals?
FDA Drugs@FDA, the Orange Book, FDA shortage records and Teva’s regulatory disclosures provide the principal public sources for product-level verification.
What is the biggest strategic risk for Actavis Elizabeth?
The principal risk is simultaneous exposure to price erosion and operational complexity: multiple generic entrants can reduce margins while FDA compliance, supply interruptions or manufacturing transfers can limit the ability to capture available volume.
References
-
Teva Pharmaceutical Industries Ltd. (2016). Teva completes acquisition of Allergan’s global generic pharmaceuticals business. https://www.teva.com/news-and-media/
-
Teva Pharmaceutical Industries Ltd. (2024). Annual report on Form 20-F. https://www.sec.gov/edgar/browse/?CIK=818686
-
U.S. Food and Drug Administration. (2024a). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. Food and Drug Administration. (2024c). Biosimilar and interchangeable biosimilar products. https://www.fda.gov/drugs/biosimilars/biosimilar-and-interchangeable-biosimilar-products
-
Federal Trade Commission. (2013). Pay-for-delay: When drug companies agree not to compete. https://www.ftc.gov/news-events/topics/competition-enforcement/health-care
